Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Provectus BiopharmaceuticalsPVCT -4.00% EV-to-EBIT is -5.10 as of Aug. 03, 2026. The stock has 3 warning signs investors should review. Among 387 Biotechnology companies, Provectus Biopharmaceuticals ranks worse than 258397.67% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Provectus Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was $23.94 Mil.
Provectus Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals EV-to-EBIT Related Terms
Provectus Biopharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Provectus Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provectus Biopharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Provectus Biopharmaceuticals's EV-to-EBIT falls into.
Provectus Biopharmaceuticals's current Enterprise Value is $27.77 Mil.
Provectus Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Provectus Biopharmaceuticals (PVCT) has a EV-to-EBIT of -5.10 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 387 companies in the Biotechnology industry.
Is Provectus Biopharmaceuticals' EV-to-EBIT too high?
Provectus Biopharmaceuticals' current EV-to-EBIT is -5.10. Based on the distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Provectus Biopharmaceuticals' EV-to-EBIT compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #999999 out of 387 companies for EV-to-EBIT. This places Provectus Biopharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 12.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Provectus Biopharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provectus Biopharmaceuticals's current EV-to-EBIT is -5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current EV-to-EBIT of -5.10. The current EV-to-EBIT is -5.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current EV-to-EBIT is -5.10 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PVCT has been successfully added to your 
